Japan's Tanabe Pharma, Switzerland's Covagen In Biospecific-Protein Pact
This article was originally published in PharmAsia News
Tanabe Pharma and Covagen have agreed to a collaboration and licensing arrangement the calls for the Japan drug maker to provide $5.2 million up front for research and development of the Swiss company's biospecific proteins. Under the arrangement,
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.